Alnylam Pharmaceuticals, Inc. vs Dr. Reddy's Laboratories Limited: Examining Key Revenue Metrics

Alnylam vs. Dr. Reddy's: A Decade of Revenue Growth

__timestampAlnylam Pharmaceuticals, Inc.Dr. Reddy's Laboratories Limited
Wednesday, January 1, 201450561000132170000000
Thursday, January 1, 201541097000148189000000
Friday, January 1, 201647159000154708000000
Sunday, January 1, 201789912000140809000000
Monday, January 1, 201874908000142028000000
Tuesday, January 1, 2019219750000153851000000
Wednesday, January 1, 2020492853000174600000000
Friday, January 1, 2021844287000189722000000
Saturday, January 1, 20221037418000214391000000
Sunday, January 1, 20231828292000245879000000
Monday, January 1, 20242248243000279164000000
Loading chart...

Unleashing insights

A Tale of Two Pharmaceutical Giants: Alnylam vs. Dr. Reddy's

In the ever-evolving landscape of pharmaceuticals, Alnylam Pharmaceuticals, Inc. and Dr. Reddy's Laboratories Limited stand as titans, each with a unique trajectory. Over the past decade, Alnylam has seen a meteoric rise, with revenue surging from a modest $50 million in 2014 to an impressive $1.8 billion by 2023. This represents a staggering growth of over 3,500%, underscoring its innovative prowess in RNA interference therapeutics.

Conversely, Dr. Reddy's Laboratories, a stalwart in generic drugs, has maintained a steady revenue stream, growing from $132 billion in 2014 to $246 billion in 2023, marking an 86% increase. This stability highlights its robust market presence and strategic expansions.

While Alnylam's data for 2024 remains elusive, Dr. Reddy's projects a continued upward trend, potentially reaching $279 billion. This comparison not only showcases their financial journeys but also reflects broader industry trends.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025